Dividende

Total dividende exercice 2018: € 0,000*

Dividende final

montant proposé
€ 0,000
date de l'approbation
mai 7, 2019
date ex-coupon
date du paiement

L'histoire des dividendes

événements financiers

Information de l'entreprise

Malheureusement, nous ne disposons pas encore de cette information en néerlandais. Maintenant, la version Anglais s'est affichée.

source: company website, January 2019

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.  
argenx is listed on the Euronext Brussels exchange under the symbol ARGX.

Politique de dividende

Malheureusement, nous ne disposons pas encore de cette information en néerlandais. Maintenant, la version Anglais s'est affichée.

Source: annual report 2017

We do not expect to pay cash dividends in the foreseeable future.